Canadian biopharmaceutical company Lorus Therapeutics Inc. (LOR.TO,LRUSF.PK) posted a narrower loss in the third quarter.
The company posted third-quarter net loss of C$1.0 million or C$0.05per share, narrower than than C$1.5 million or C$0.10 per share last year. Lorus Therapeutics attributed the wider net loss mainly to higher general and administrative, and research and development expenditures.
The company did not generate any revenues in both the quarters.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org